跳至主要内容
临床试验/NCT07709611
NCT07709611尚未招募4 期

Comparison of Protein Absorption Efficiency Between Peptide and Whole Protein Enteral Nutrition Preparations in High-risk Groups With Pancreatic Exocrine Insufficiency in the ICU

Shanghai 10th People's Hospital1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2026年7月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
250
试验地点
1
主要终点
Urine 3-methylhistidine concentration

研究概览

简要总结

The goal of this clinical trial is to systematically evaluate whether peptide-type enteral nutrition (EN) formulations improve protein uptake efficiency in high-risk groups at ICU PEI, using targeted amino acid metabolomics and gut microbiota co-metabolomics as core quantitative indicators.

Researchers will compare protein absorption efficiency of short-chain peptide and complete protein enteral nutrition formulas in high-risk populations for PEI in the ICU

Participants will:

Enteral nutrition was administered for ICU critically ill patients with high-risk factors for PEI

详细描述

The study subjects that meet the inclusion criteria will be randomly assigned in a 1:1 ratio to the peptide group and the whole protein group according to the following allocation scheme:

  1. Peptide Group: Receives nutritional support therapy with a peptide-based enteral nutrition (EN) formulation. The selected formulation must contain 5 g of protein per 100 ml and be composed entirely of hydrolyzed whey protein, which can be absorbed by the intestine without the need for thorough digestion by pancreatic enzymes.
  2. Whole Protein Group: Receives nutritional support therapy with a whole protein-based EN formulation. The selected formulation also contains 5 g of protein per 100 ml and consists of intact protein components, which require digestion and breakdown by pancreatic enzymes before being absorbed.

Both groups of study subjects will strictly follow the 2025 ASPEN Guidelines for Nutritional Therapy in Critically Ill Patients and the relevant expert consensus on critical care nutrition in China. Apart from the difference in the type of EN formulation, all other treatment measures (including anti-infection therapy, organ function support, gastrointestinal motility regulation, sedation and analgesia) will be carried out in accordance with standard ICU clinical practices to ensure consistency in the baseline treatment conditions between the two groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age≥ 18 years old, no gender restriction;
  • Meet the criteria for high-risk groups for PEI;
  • AGI≤ Class II, hemodynamically stable, meeting EN initiation criteria;
  • Estimated duration of enteral nutrition support therapy: ≥7 days;
  • The subject or their legally authorized family member must sign the informed consent form

排除标准

  • Patients who have been clearly diagnosed with PEI or chronic persistent PEI;
  • Patients who have contraindications to enteral nutrition therapy;
  • Patients with severely impaired liver or kidney function;
  • Patients who suffer from amino acid metabolism disorders, severe malnutrition, or cachexia;
  • Patients who have received pancreatic enzyme replacement therapy or taken any medications that may affect protein absorption within 7 days prior to enrollment;
  • Patients for whom the expected length of ICU stay is less than 7 days;
  • Pregnant or lactating women, as well as patients with mental illnesses;
  • Patients who are allergic to any component of the study medication.

结局指标

主要结局

Urine 3-methylhistidine concentration

时间窗: Week 1

Branched-chain amino acid concentration

时间窗: Week 1

Citrulline concentration

时间窗: Week 1

次要结局

  • Fecal elastase-1(Week 1)
  • Serum pancreatic lipase levels(Week 1)
  • Serum pancreatic amylase levels(Week 1)
  • Plasma diamine oxidase levels(Week 1)
  • Plasma D-lactate level(Week 1)
  • P-cresol content in feces(Week 1)
  • Indole content in feces(Week 1)
  • Ultrasound is used to detect the thickness of the rectus femoris and assess the degree of muscle attenuation(Week 2)
  • 28-day all-cause mortality(Week 4)

研究者

发起方
Shanghai 10th People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Sheng Wang MD PhD

Chief physician

Shanghai Tongji Hospital, Tongji University School of Medicine

研究点 (1)

Loading locations...

相似试验